Hasegawa Masaichi, Nishigaki Naohiko, Washio Yoshiaki, Kano Kazuya, Harris Philip A, Sato Hideyuki, Mori Ichiro, West Rob I, Shibahara Megumi, Toyoda Hiroko, Wang Liping, Nolte Robert T, Veal James M, Cheung Mui
Tsukuba Research Laboratories, GlaxoSmithKline K.K., 43 Wadai, Tsukuba, Ibaraki 300-4247, Japan.
J Med Chem. 2007 Sep 6;50(18):4453-70. doi: 10.1021/jm0611051. Epub 2007 Aug 4.
We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the N1 nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the N1 nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.
我们在此公开了一类新型的苯并咪唑脲化学系列化合物,它们是血管内皮生长因子受体-2(VEGFR-2)和酪氨酸激酶受体-2(TIE-2)的抑制剂,这两种受体均与血管生成有关。构效关系(SAR)研究阐明了苯并咪唑(E片段)和脲(B片段)部分的N1氮的关键作用。当苯并咪唑脲化合物与VEGFR-2酶结合时,N1氮和脲部分的作用通过X射线晶体学得以阐明,这也支持了SAR结果。左侧苯环(A片段)占据了后口袋,其中3-疏水取代基有利于TIE-2活性。